Access the full text.
Sign up today, get DeepDyve free for 14 days.
R. Okita, A. Maeda, K. Shimizu, Yuji Nojima, S. Saisho, M. Nakata (2017)
PD-L1 overexpression is partially regulated by EGFR/HER2 signaling and associated with poor prognosis in patients with non-small-cell lung cancerCancer Immunology, Immunotherapy, 66
R. Schreiber, L. Old, M. Smyth (2011)
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and PromotionScience, 331
Hui Yu, C. Batenchuk, A. Badzio, T. Boyle, P. Czapiewski, D. Chan, Xian Lu, D. Gao, K. Ellison, Ashley Kowalewski, C. Rivard, R. Dziadziuszko, Caicun Zhou, M. Hussein, D. Richards, S. Wilks, M. Monte, W. Edenfield, J. Goldschmidt, R. Page, B. Ulrich, D. Waterhouse, S. Close, J. Jassem, K. Kulig, F. Hirsch (2017)
PD‐L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung CancerJournal of Thoracic Oncology, 12
C. Cruz, L. Tanoue, R. Matthay (2011)
Lung cancer: epidemiology, etiology, and prevention.Clinics in chest medicine, 32 4
J. Sheng, W. Fang, Juan Yu, N. Chen, J. Zhan, Yuxiang Ma, Yun-peng Yang, Yanhuang, Hongyun Zhao, Li Zhang (2016)
Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancerScientific Reports, 6
Ramon Mello, Ana Veloso, Paulo Catarina, S. Nadine, G. Antoniou (2016)
Potential role of immunotherapy in advanced non-small-cell lung cancerOncoTargets and therapy, 10
Xiaohua Shi, Shafei Wu, Jian Sun, Yuanyuan Liu, X. Zeng, Z. Liang (2017)
PD-L1 expression in lung adenosquamous carcinomas compared with the more common variants of non-small cell lung cancerScientific Reports, 7
M. Mino‐Kenudson (2016)
Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?Cancer Biology & Medicine, 13
W. Cooper, Thang Tran, R. Vilain, J. Madore, C. Selinger, M. Kohonen-Corish, P. Yip, Bing Yu, S. O'toole, B. McCaughan, J. Yearley, L. Horvath, S. Kao, M. Boyer, R. Scolyer (2015)
PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.Lung cancer, 89 2
E. Garon, N. Rizvi, R. Hui, N. Leighl, A. Balmanoukian, J. Eder, A. Patnaik, C. Aggarwal, M. Gubens, L. Horn, E. Carcereny, M. Ahn, E. Felip, Jong-Seok Lee, M. Hellmann, O. Hamid, J. Goldman, J. Soria, M. Dolled-Filhart, R. Rutledge, Jin Zhang, J. Lunceford, Reshma Rangwala, G. Lubiniecki, C. Roach, K. Emancipator, L. Gandhi (2015)
Pembrolizumab for the treatment of non-small-cell lung cancer.The New England journal of medicine, 372 21
V. Anagnostou, J. Brahmer (2015)
Cancer Immunotherapy: A Future Paradigm Shift in the Treatment of Non–Small Cell Lung CancerClinical Cancer Research, 21
J. Sunshine, J. Taube (2015)
PD-1/PD-L1 inhibitors.Current opinion in pharmacology, 23
J. Soria, A. Marabelle, J. Brahmer, S. Gettinger (2015)
Immune Checkpoint Modulation for Non–Small Cell Lung CancerClinical Cancer Research, 21
B. Lippitz (2013)
Cytokine patterns in patients with cancer: a systematic review.The Lancet. Oncology, 14 6
V. Velcheti, K. Schalper, Daniel Carvajal, V. Anagnostou, K. Syrigos, M. Sznol, R. Herbst, S. Gettinger, Lieping Chen, D. Rimm (2014)
Programmed death ligand-1 expression in non-small cell lung cancerLaboratory Investigation, 94
J. Molina, Ping Yang, S. Cassivi, S. Schild, A. Adjei (2008)
Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.Mayo Clinic proceedings, 83 5
A. Corthay (2014)
Does the Immune System Naturally Protect Against Cancer?Frontiers in Immunology, 5
I. Cree, R. Booton, P. Cane, J. Gosney, M. Ibrahim, K. Kerr, R. Lal, C. Lewanski, N. Navani, A. Nicholson, M. Nicolson, Y. Summers (2016)
PD‐L1 testing for lung cancer in the UK: recognizing the challenges for implementationHistopathology, 69
M. Ilié, V. Hofman, M. Dietel, J. Soria, P. Hofman (2016)
Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patientsVirchows Archiv, 468
S. Champiat, E. Ileana, G. Giaccone, B. Besse, G. Mountzios, A. Eggermont, J. Soria (2014)
Incorporating Immune-Checkpoint Inhibitors into Systemic Therapy of NSCLCJournal of Thoracic Oncology, 9
H. Borghaei, L. Paz-Ares, L. Horn, D. Spigel, M. Steins, N. Ready, L. Chow, E. Vokes, E. Felip, E. Holgado, F. Barlesi, M. Kohlhäufl, O. Arrieta, M. Burgio, J. Fayette, H. Léna, E. Poddubskaya, D. Gerber, S. Gettinger, C. Rudin, N. Rizvi, L. Crinò, G. Blumenschein, S. Antonia, C. Dorange, C. Harbison, F. Finckenstein, J. Brahmer (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.The New England journal of medicine, 373 17
R. Ibrahim, R. Stewart, A. Shalabi (2015)
PD-L1 blockade for cancer treatment: MEDI4736.Seminars in oncology, 42 3
F. Garrido, F. Ruiz-Cabello, T. Cabrera, J. Perez-Villar, M. López-Botet, M. Duggan-Keen, P. Stern (1997)
Implications for immunosurveillance of altered HLA class I phenotypes in human tumours.Immunology today, 18 2
J. Brahmer, K. Reckamp, P. Baas, L. Crinò, W. Eberhardt, E. Poddubskaya, S. Antonia, A. Płużański, E. Vokes, E. Holgado, D. Waterhouse, N. Ready, J. Gainor, O. Frontera, L. Havel, M. Steins, M. Garassino, J. Aerts, M. Dómine, L. Paz-Ares, M. Reck, C. Baudelet, C. Harbison, B. Lestini, D. Spigel (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.The New England journal of medicine, 373 2
Yanbin Chen, C. Mu, Jian-an Huang (2012)
Clinical Significance of Programmed Death-1 Ligand-1 Expression in Patients with Non-Small Cell Lung Cancer: A 5-year-follow-up StudyTumori Journal, 98
Kareem Mohammed, Abdulwahab Ewaz, C. Cohen, M. Siddiqui (2017)
Double staining: diagnostic utility in non-small cell lung carcinoma in the era of tissue conservation.Journal of the American Society of Cytopathology, 6 4
Molina (2008)
Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorshipMayo Clin Proc, 83
Background:Programmed death receptor and programmed death ligand (PD-L1) are immunoregulatory proteins. Nonsmall cell lung cancer bypasses the immune system through the induction of protumorigenic immunosuppressive changes. The better understanding of immunology and antitumor immune responses has brought the promising development of novel immunotherapy agents like programmed death receptor checkpoint inhibitors. The aim of this study was to investigate the expression of PD-L1 in lung adenocarcinoma (ADC), comparing 2 different technologies: immunohistochemistry (IHC) by 2 methods versus RNA in situ hybridization (RISH).Methodology:In total, 20 cases of ADC of the lung and 4 samples of metastatic colon ADC were selected. Evaluation of PD-L1 expression was performed by IHC and RISH. RISH was performed using RNAscope. Both methods were scored in tumor cells and quantified using combined intensity and proportion scores.Results:Eight of 20 (40%) lung ADC and 2 of 4 (50%) colon ADC were positive for PD-L1 with Cell Signaling IHC, and 65% lung ADC were positive by Dako IHC (13/20). All 4 cases of colon ADC were negative. When evaluated by RISH, 12 lung ADC (60%) and 1 colon ADC (25%) were PD-L1 positive.Conclusions:RNAscope probes provide sensitive and specific detection of PD-L1 in lung ADC. Both IHC methods (Cell Signaling and Dako) show PD-L1 expression, with the Dako method more sensitive (40% vs. 65%). This study illustrates the utility of RISH and Cell Signaling IHC as complementary diagnostic tests, and Food and Drug Administration approved Dako IHC as a companion diagnostic test.
Applied Immunohistochemistry & Molecular Morphology – Wolters Kluwer Health
Published: Sep 1, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.